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Upon completion of this article, the reader should be able to do the following: (1) Describe the rationale for evaluating a multijoint implanted neuroprosthesis to improve walking after stroke; (2) Understand the study design and conclusions that can be inferred as a result of the design; and (3) Discuss the statistical significance and clinical relevance of changes between (a) volitional walking at baseline, (b) volitional walking after training, and (c) walking with stimulation after training.
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Improving gait requires a therapy or intervention that addresses impairments at multiple joints simultaneously. Therapeutic benefits are those maintained after an intervention is removed, whereas neuroprosthetic benefits are only derived through the use of an assistive device and are not realized when the device is not in use. Neuroprosthetic interventions in stroke using electrical stimulation have primarily focused on dorsiflexion assistance to prevent foot drop. Although dorsiflexion assist with common peroneal nerve stimulation can positively affect walking, its neuroprosthetic 10 and therapeutic 11, 12 effects are comparable to an ankle foot orthosis. Surface and implantable peroneal nerve stimulators are commercially available to prevent foot drop, but many patients have deficits at the hip, knee, and ankle that require multijoint stimulation to realize significant benefit. 13 The development of multichannel implantable pulse generators (IPGs) could provide an opportunity to improve walking function in moderately and severely impaired patients by providing assistance to compensate for multiple gait deficits at once. 14 For example, activating knee flexors in early swing has the potential to correct stiff-legged gait to improve toe clearance during swing 15 and reduce the chance of tripping and falling. Activation of knee and hip extensors during stance improves stability and can prevent the leg from buckling, also reducing the chance of falls. Additionally, activation of hip flexors and extensors and plantar flexors provide most of the power to move the body forward to improve walking speed. 16, 17 Thus, the application of multichannel IPGs could significantly improve poststroke gait by correcting deficits at the hip, knee, and ankle to simultaneously prevent falls, improve stability, and increase speed. Multijoint movement by means of stimulation with percutaneous electrodes has therapeutically improved joint kinematics 18 and increased walking distance. 19 Similarly, multijoint movement with surface stimulation has been shown to have a neuroprosthetic effect by reducing impairments, including increased knee and hip flexion during swing and knee stability and ankle push-off during stance. 13 This is the first report of the neuroprosthetic and therapeutic effects of a fully implanted 8-channel pulse generator for multijoint movement to assist walking after stroke. We hypothesized that there would be both a therapeutic effect from gait training with stimulation over time, as well as a neuroprosthetic effect while interactively using the stimulation during walking. The research protocol was approved by the medical center_s Institutional Review Board and subject_s consent was obtained and documented before participation in the study.
METHODS

Participant
The participant was a 64-year-old man, 1 year and 9 months after hemorrhagic stroke affecting the right lateral basal ganglia and frontal cortex. He exhibited left-sided hemiparesis and left hemisensory deficits. Proprioception was absent in the ankle and diminished at the knee. Tactile sensation Neuroprosthesis for Improving Poststroke Gait was impaired but not absent on the affected side and was consistent along the extremities. Although his vision was intact, he had left hemineglect. He was on antispasticity medication.
He was a household ambulator with a straight cane or a quad cane with contact guard assistance. However, he was transported in a wheelchair in the community. He did not fall in the year before participating in the study. His gait was limited by a combination of decreased strength, limited independent joint movement, and moderate hypertonia. He exhibited a lower extremity extensor synergy with coupled hip, knee, and ankle extension. He had weak hip and knee flexors and ankle dorsiflexors, walking with a stiff-legged gait that was compensated by hip hiking. He wore a double upright ankle foot orthosis to limit foot drop. Baseline manual muscle test 20 and modified Ashworth scale 21 scores for the affected lower extremity are provided in Table 1 . Both limbs displayed weakness, but the left side was significantly more impaired. His left upper extremity was severely impaired with no volitional movement and moderate hypertonia. During gait, the scapula was protracted and elbow extended whereas the affected arm hung anterior to the body. No pain was reported during walking.
Neuroprosthesis
The neuroprosthesis consists of an 8-channel IPG, 22 8 intramuscular electrodes, 23 and an external control unit (Fig. 1A) . The IPG produces 8 independent channels of current-controlled, chargebalanced biphasic pulses at a fixed amplitude of 20 mA in temporal patterns with variable interpulse interval and pulse duration. The IPG length, width, and depths are 8.9, 3.4, and 1.0 cm, respectively. The external control unit transmits power and stimulation commands to the implanted stimulator via a transcutaneous radiofrequency antenna placed externally over the IPG. Figure 1B shows the participant walking with the system.
Surgical Planning and Surgical Procedure
Presurgical surface and needle stimulation were used to verify that functional lower limb movements could be attained without pain or discomfort. Based on the participant_s motor deficits (Table 1) and the responses to stimulation, the following muscles were targeted for implantation: tensor fasciae latae (hip flexor), sartorius (hip and knee flexor), gluteus maximus (hip extensor), short head of biceps femoris (knee flexor), quadriceps (knee extensor), tibialis anterior/peroneus longus (ankle dorsiflexors), and gastrocnemius (ankle plantar flexor). A single intramuscular electrode was inserted in the quadriceps for knee extension, but the recruitment of specific muscles was not evaluated. One electrode, along with a backup for redundancy, was implanted to activate the common peroneal nerve targeting tibialis anterior and peroneus longus to produce balanced dorsiflexion.
The surgery was performed with the participant under general anesthesia. Motor points for muscles were identified based on anatomical landmarks and neuromuscular anatomy. 24 A needle probe was used to locate the motor point of each muscle producing a strong isolated contraction. Next, a cannula was passed over the probe to a depth just short of the tip; the probe was then removed and the electrode was inserted with a holder that ensured the tip of the electrode ended just beyond the cannula at the motor point. The cannula was removed, and the response to the stimulation was confirmed before the lead was tunneled subcutaneously to the lower abdominal area for connection to the IPG. The IPG was inserted into a subfascial pocket on the abdominal wall half way between the anterior superior iliac spine and umbilicus of the subject_s affected side. Before closing all incisions, muscle contractions and proper device operation were verified. The subject was discharged 2 days after surgery with unrestricted activity limited only by postsurgical discomfort.
Gait Training
Six weeks after surgery, stimulated responses were measured for each electrode. Joint movements due to stimulation were evaluated while the participant was relaxed and either supine or lying on his side. Stimulation produced the expected movements except the electrode targeting the short head of biceps femoris, which produced strong ankle plantar flexion followed by knee flexion, suggesting recruitment of the tibial component of the sciatic nerve. One of the electrodes targeting the common peroneal nerve for dorsiflexion produced a withdrawal response resulting in simultaneous hip and knee flexion. Muscle contraction strength was controlled first by varying pulse width to modulate spatial muscle fiber recruitment and second by varying frequency to modulate their temporal summation. 25 Stimulation frequencies ranged from 20 to 33 Hz, with 25 Hz used during the early portion of the swing phase and 20 Hz during mid and terminal swing. Pulse frequency was 33 Hz during the stance phase. Maximum pulse widths varied from 25 to 250 Ks, depending on the electrode recruitment properties. Exercise stimulation patterns were created for home use to improve muscle strength and fatigue resistance. Exercise consisted of 2 patterns that alternated between stimulation to 2 groups of muscles: (1a) tibialis anterior and peroneus longus, (1b) gastrocnemius and short head of the biceps; and (2a) tensor fasciae latae, sartorius, tibialis anterior, and peroneus longus, and (2b) gluteus maximus. Each muscle set was stimulated independently with a burst of pulses at 20 Hz for approximately 200 ms followed by a 500-ms rest period before repeating the cycle. The limb was free to move, and no resistance was applied. The participant used each exercise stimulation pattern for half an hour a day while sitting or lying supine.
The participant came to the laboratory once or twice a week for 30 weeks of 2-to 3-hour sessions of gait training for a total of 46 sessions. The stimulation pattern emulating normal muscle activity during gait was developed and modified heuristically over several sessions according to established protocols. 26 Multiple changes to the stimulation pattern were made during early sessions of gait training. Stimulation pattern tuning focused on walking coordination and user comfort. During the sessions, the therapist worked with the participant to progress from a step-to gait to a 2-point gait, learn to shift weight to the affected side, practice starting and stopping walking, and to reduce exaggerated hip and knee flexion and lengthen the step on the unaffected side. Stimulus patterns were adjusted accordingly. During volitional walking, the participant used a step-to gait moving his cane, then affected leg, then unaffected leg. He learned to use a 2-point gait while walking with stimulation, simultaneously moving the affected leg and the cane.
Step Initiation Control
The stimulation pattern is controlled by a heel switch in the sole of the shoe on the affected side. Heel off triggers a pattern associated with the swing phase of gait, whereas initial contact (heel strike) triggers a pattern associated with stance (Fig. 2) . The swing phase pattern consists of activation of the tensor fasciae latae, sartorius, and tibialis anterior with peroneus longus to provide hip and knee flexion and ankle dorsiflexion. After a delay, tensor fascia latae and sartorius stimulation is ramped down, whereas stimulation to the quadriceps for knee extension is ramped up in preparation for heel strike. After heel strike, the stance phase pattern consists of turning off tibialis anterior and peroneus longus and ramping down stimulation to quadriceps while initiating gluteus maximus activation for hip extension.
Outcome Assessments
Assessments were performed as follows: (1) at baseline without stimulation before gait training (video 1: http://links.lww.com/PHM/A255), (2) without stimulation after gait training (video 2: http:// links.lww.com/PHM/A254), and (3) with stimulation after gait training (video 3: http://links.lww.com/ PHM/A256). Walking speed was the primary outcome measure. Endurance and spatial-temporal characteristics were secondary measures. Gait speed was measured with a 10-m walk test (10MWT) and over a longer distance with a 6-minute walk test (6MWT). The distance walked was recorded at 2 minutes to validate whether walking speed was consistent during the 6MWT or if the participant slowed down. Maximum walking distance until the participant wanted to stop owing to fatigue was a measure of endurance. Distance was measured at 2-minute intervals. All measures were taken either in the laboratory (10MWT) or in cleared hospital hallways (6MWT and maximum distance). Spatial-temporal gait parameters were acquired with a 16-camera Vicon MX40 (Vicon Inc., Oxford, UK) system over an 8-m walkway with markers on the heel, toe, and ankle. At least 5 strides were collected for each trial condition.
Baseline walking only tested volitional effort. Assessments after gait training included walking with and without the IPG turned on. A minimum of 5 trials were collected for each condition during the 10MWT. Two trials were collected for each condition during the 6MWT. The participant rested 3 minutes between 10MWT and 10 minutes between 6MWT trials.
Data Analysis
A one-way analysis of variance with unbalanced replicates was used to evaluate whether there was a change in the outcome measures between 3 walking conditions. P values less than 0.05 were considered statistically significant differences. Post hoc paired t tests with Bonferroni correction provided comparisons between conditions to determine the contributing effects of the intervention, accounting for the multiple comparisons. Comparison of volitional walking before and after training (conditions 1 and 2) determined the therapeutic effect. Comparing volitional walking and stimulated walking after training (conditions 2 and 3) determined the neuroprosthetic effect. Volitional walking before training and walking with stimulation after training (conditions 1 and 3) were compared to describe the total effect of the multijoint intervention.
RESULTS
The participant consistently used a 2-point gait while walking with stimulation, but it was necessary to complete all volitional assessments using a step-to gait owing to safety concerns. Volitional walking with the 2-point gait resulted in repeated foot catches and trips, which could have produced a fall without providing assistance. There were no toe catches during the assessments, either with or without stimulation using 2-point and step-to gait, respectively. There were no falls during the study period. Walking speed was averaged across trials for each walking condition during the 10MWT and 6MWT. Figure 3 shows average walking speed for the 3 test conditions.
Comparing the 10MWT baseline walking speed with volitional speed after training showed an increase Figure 4 , with the total distance walked over time in the upper panel and the interval distance walked every 2 minutes in the lower panel. Fluctuations around the 30-minute mark during the stimulation condition were due to the need to stand for a brief rest break.
There was a significant difference in most of the spatial-temporal parameters during volitional walking after training as compared to baseline except for affected swing duration, unaffected step length, and affected stance/swing ratio. Similarly, there was a significant change in most of the parameters after training between walking with and without stimulation except for unaffected double support, affected swing duration, and affected step length ( Table 2 ). The largest change was in the affected double support time, which decreased after training and further decreased while walking with stimulation.
DISCUSSION
These results are the first report of the benefits of a fully implanted pulse generator (IPG) for hip, knee, and ankle control in an individual with stroke. The data demonstrate that stimulation of the hip and knee flexors and extensors and ankle dorsiflexors could improve walking speed, step length, stance and swing times, symmetry, and cadence. Whereas FIGURE 3 Gait speed at baseline and after training comparing volitional walking with walking with stimulation. Top graph shows mean (SD) for 10-m walk, whereas the bottom graph shows mean (SD) for the timed 6-minute walk test.
FIGURE 4 Maximum distance walked (top graph)
and 2-minute incremental distance (bottom graph).
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Neuroprosthesis for Improving Poststroke Gait the participant experienced both therapeutic and neuroprosthetic benefits, only the neuroprosthetic effect is representative of a clinically relevant impact on walking speed. A 0.16-m/s improvement in gait speed is considered clinically relevant based on improvements correlated with changes in the Modified Rankin Scale, a measure of functional independence. 27 This threshold is consistent with the generally accepted 0.14-m/s change to describe clinically relevant declines in gait speed and function. 28 The therapeutic changes to voluntary walking due to gait training with stimulation included reduction in affected double support, increase in unaffected swing duration, and increases in affected and unaffected stride length. These improvements are likely the result of increased strength on the affected side, and improved confidence and stability allowing for longer steps and increased time in single stance. Maximum walking distance at the start of gait training was limited to approximately 76 m owing to fatigue. The maximum walk distance of 301 m without stimulation after training suggests a clinically relevant improvement in endurance; however, changes in walking speed of 0.05 m/s are not considered clinically significant. 27 Some studies of peroneal nerve stimulation have shown similar therapeutic benefits, 11, 12 whereas other studies of peroneal nerve stimulation have had a larger therapeutic effect on walking speed. 29 Although gait training was not the focus of the study, the changes in gait speed are also comparable to those produced by therapist-or robot-assisted locomotor training on a treadmill (0.06 m/s) in a group with similar impairments. 30 Although therapy is provided over a limited period of time, persistent use of the device during walking may provide ongoing training that maintains both muscle conditioning and cardiovascular health. This use may encourage activity and prevent atrophy and disuse. The neuroprosthetic benefit produced clinically relevant improvements in gait speed. There was an increase in gait speed of 0.37 m/s, which exceeds 0.16 m/s normally recognized as clinically significant. 27 An improvement in the speed of walking from 0.35 m/s to 0.72 m/s represents a potential change in ambulation status from household to limited community ambulator. 7 One contributor to the increased speed was the transition from a step-to gait to a 2-point gait, which produced the dramatic decrease in affected double support. The change in gait pattern with stimulation was enabled by the toe clearance produced by the additional knee flexion as evidenced by the foot catches during attempts at volitional 2-point gait even while wearing an ankle foot orthosis. In addition to the decrease in affected double support time, there was an increase in affected stride and step length, and an increase in unaffected stride and step length and swing time. The increase in unaffected step length improved step symmetry. The unaffected and affected stance/swing ratios are both approaching more typical ratios (60:40). The improvements in unaffected step swing time and step length indicate better stability resulting from stimulation of hip extensors during stance. Although the participant is not walking with stimulation outside of the laboratory, he reports increased walking in the neighborhood, which is an improvement over previous reports of only household ambulation. These reports suggest that transferring use of the system to the community would further enable community ambulation. The participant reports that he enjoys walking with stimulation and appreciates the exercise as the stimulation enables him to walk significantly faster. Maximum walk trials showed a consistent increase in walking speed, duration, and distance. The therapeutic effect is likely a result of muscle conditioning during stimulated exercise and gait training. However, the study design prevents determining the relative contribution of the stimulation and gait training. The neuroprosthetic effect of walking longer distances at a faster speed suggests that the stimulation did not increase muscle fatigue in a way that limited gait. Home exercise with stimulation presumably contributed to this effect. While walking faster with stimulation uses more energy, the participant effectively maintained a consistent gait speed. Although 43-minute walks may not be typical, the ability to walk at will for long periods of time is useful for community ambulation and participation and demonstrates that walking with stimulation can be maintained for functionally relevant periods of time.
Neuroprosthetic improvements suggest that daily use of an implanted system could have significant clinical relevance to a portion of the stroke population. Prior studies of implanted foot drop stimulators produced neuroprosthetic improvements of 0.08 and 0.03 m/s, 31, 32 whereas studies of surface peroneal nerve stimulation produced increases of 0.06 m/s 10 and 0.08 m/s. 29 Only the NESS L300Plus (Bioness Inc, Valencia, CA) incorporates surface stimulation of knee flexors or extensors, which is associated with improvement in gait speed over peroneal nerve stimulation of 0.04 m/s, 33 where 13% of participants used quadriceps stimulation and 87% used hamstrings stimulation. However, there are currently no commercially available systems to provide effective active hip flexion for home use; such an approach would require an IPG. Poststroke impairment covers a broad spectrum of gait deficits, and it is important to recognize that presents unique challenges to the design and implementation of assistive devices. Many patients may have sufficient residual function to obviate the potential benefits of a multijoint neuroprosthesis. However, patients with limited hip and knee control may require multijoint stimulation to fully realize the benefits of an implanted stimulation system, instead of one that concentrates only at the ankle. In the context of the other studies, the data presented here suggest that there is a spectrum of stroke survivors who would clinically benefit from hip and knee stimulation, in addition to ankle stimulation. Although this single-subject study provides evidence of efficacy in a single individual with the subject acting as his own concurrent and longitudinal control, the results cannot be generalized without appropriately designed larger-scale trial. Future studies would need to recruit additional participants to ensure independent samples and determine what portion of the stroke population would truly benefit from a multijoint device. Increased sample size would also ensure a priori independence of samples for statistical analysis. Whereas the residuals of the analysis of variance were uncorrelated and indicated independence, repeated measures from the same individual in a single-subject study design may not be independent. Although this participant did not have any complications from surgery or device malfunction over the course of the study, these aspects would need to be considered in future assessments within the stroke population.
Whereas statistically significant improvements in voluntary walking were observed after the training, the goal of training was to maximize voluntary function before quantifying neuroprosthetic effects of multijoint stimulation. The current study design does not differentiate between factors contributing to improvements in voluntary function: gait training alone, incorporating stimulation into gait training, and home stimulation exercises. Nevertheless, the positive neuroprosthetic effect of stimulation on the gait of this single subject over voluntary function after gait training with stimulation is clear.
There are many opportunities to refine this intervention and demonstrate its use during ambulation in the home and community, but these data demonstrate that implanted stimulation system for multijoint control is a promising intervention to provide assistance to stroke survivors during daily walking.
